Incidence of acquired demyelination of the CNS in Canadian children
The incidence of acquired demyelination of the CNS (acquired demyelinating syndromes [ADS]) in children is unknown. It is important that physicians recognize the features of ADS to facilitate care and to appreciate the future risk of multiple sclerosis (MS). To determine the incidence, clinical feat...
Gespeichert in:
| Veröffentlicht in: | Neurology 2009-01, Vol.72 (3), p.232-239 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 239 |
|---|---|
| container_issue | 3 |
| container_start_page | 232 |
| container_title | Neurology |
| container_volume | 72 |
| creator | BANWELL, B KENNEDY, J SEBIRE, G MEANEY, B DILENGE, M.-E LORTIE, A WHITING, S DOJA, A LEVIN, S MACDONALD, E. A MEEK, D WOOD, E SADOVNICK, D LOWRY, N BUCKLEY, D YIM, C AWUKU, M GUIMOND, C COOPER, P GRAND'MAISON, F BAIRD, J. B BHAN, V BAR-OR, A ARNOLD, D. L MAGALHAES, S WAMBERA, K CONNOLLY, M. B YAGER, J MAH, J. K SHAH, N |
| description | The incidence of acquired demyelination of the CNS (acquired demyelinating syndromes [ADS]) in children is unknown. It is important that physicians recognize the features of ADS to facilitate care and to appreciate the future risk of multiple sclerosis (MS).
To determine the incidence, clinical features, familial autoimmune history, and acute management of Canadian children with ADS.
Incidence and case-specific data were obtained through the Canadian Pediatric Surveillance Program from April 1, 2004, to March 31, 2007. Before study initiation, a survey was sent to all pediatric health care providers to determine awareness of MS as a potential outcome of ADS in children.
Two hundred nineteen children with ADS (mean age 10.5 years, range 0.66-18.0 years; female to male ratio 1.09:1) were reported. The most common presentations were optic neuritis (ON; n = 51, 23%), acute disseminated encephalomyelitis (ADEM; n = 49, 22%), and transverse myelitis (TM; n = 48, 22%). Children with ADEM were more likely to be younger than 10 years, whereas children with monolesional ADS (ON, TM, other) were more likely to be older than 10 years (p < 0.001). There were 73 incident cases per year, leading to an annual incidence of 0.9 per 100,000 Canadian children. A family history of MS was reported in 8%. Before study initiation, 65% of physicians indicated that they considered MS as a possible outcome of ADS in children. This increased to 74% in year 1, 81% in year 2, and 87% in year 3.
The incidence of pediatric acquired demyelinating syndromes (ADS) is 0.9 per 100,000 Canadian children. ADS presentations are influenced by age. |
| doi_str_mv | 10.1212/01.wnl.0000339482.84392.bd |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66829715</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66829715</sourcerecordid><originalsourceid>FETCH-LOGICAL-c290t-5e32be5edc8922831768dbaf0dd6d806e203263bdfd10b9673a7dea27283d8253</originalsourceid><addsrcrecordid>eNpFkMFKJDEQhoMo6-juK0gj6K3bSsVOJ96kcV1B9KDC3kI6VY2RnrR2ZhDf3p51WOtSh__7q-AT4lhCJVHiGcjqPQ0VzKOUPTdYmXNlsepoRyxkjbrUCv_uigUAmlKZxuyLg5xfAOawsT_EvrSyVqqBhWhvUojEKXAx9oUPb-s4MRXEyw8eYvKrOKZNsnrmor17KGIqWp88RZ-K8BwHmjj9FHu9HzL_2u5D8fT76rH9U97eX9-0l7dlQAursmaFHddMwVhEo2SjDXW-ByJNBjQjKNSqo54kdFY3yjfEHpuZJYO1OhSnX3dfp_FtzXnlljEHHgafeFxnp7VB28gNePEFhmnMeeLevU5x6acPJ8FtFDqQblbovhW6fwpdR3P5aPtl3S2ZvqtbZzNwsgV8Dn7oJz8rzP85lFBb1KA-AUb3enk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66829715</pqid></control><display><type>article</type><title>Incidence of acquired demyelination of the CNS in Canadian children</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>Journals@Ovid Complete</source><creator>BANWELL, B ; KENNEDY, J ; SEBIRE, G ; MEANEY, B ; DILENGE, M.-E ; LORTIE, A ; WHITING, S ; DOJA, A ; LEVIN, S ; MACDONALD, E. A ; MEEK, D ; WOOD, E ; SADOVNICK, D ; LOWRY, N ; BUCKLEY, D ; YIM, C ; AWUKU, M ; GUIMOND, C ; COOPER, P ; GRAND'MAISON, F ; BAIRD, J. B ; BHAN, V ; BAR-OR, A ; ARNOLD, D. L ; MAGALHAES, S ; WAMBERA, K ; CONNOLLY, M. B ; YAGER, J ; MAH, J. K ; SHAH, N</creator><creatorcontrib>BANWELL, B ; KENNEDY, J ; SEBIRE, G ; MEANEY, B ; DILENGE, M.-E ; LORTIE, A ; WHITING, S ; DOJA, A ; LEVIN, S ; MACDONALD, E. A ; MEEK, D ; WOOD, E ; SADOVNICK, D ; LOWRY, N ; BUCKLEY, D ; YIM, C ; AWUKU, M ; GUIMOND, C ; COOPER, P ; GRAND'MAISON, F ; BAIRD, J. B ; BHAN, V ; BAR-OR, A ; ARNOLD, D. L ; MAGALHAES, S ; WAMBERA, K ; CONNOLLY, M. B ; YAGER, J ; MAH, J. K ; SHAH, N</creatorcontrib><description>The incidence of acquired demyelination of the CNS (acquired demyelinating syndromes [ADS]) in children is unknown. It is important that physicians recognize the features of ADS to facilitate care and to appreciate the future risk of multiple sclerosis (MS).
To determine the incidence, clinical features, familial autoimmune history, and acute management of Canadian children with ADS.
Incidence and case-specific data were obtained through the Canadian Pediatric Surveillance Program from April 1, 2004, to March 31, 2007. Before study initiation, a survey was sent to all pediatric health care providers to determine awareness of MS as a potential outcome of ADS in children.
Two hundred nineteen children with ADS (mean age 10.5 years, range 0.66-18.0 years; female to male ratio 1.09:1) were reported. The most common presentations were optic neuritis (ON; n = 51, 23%), acute disseminated encephalomyelitis (ADEM; n = 49, 22%), and transverse myelitis (TM; n = 48, 22%). Children with ADEM were more likely to be younger than 10 years, whereas children with monolesional ADS (ON, TM, other) were more likely to be older than 10 years (p < 0.001). There were 73 incident cases per year, leading to an annual incidence of 0.9 per 100,000 Canadian children. A family history of MS was reported in 8%. Before study initiation, 65% of physicians indicated that they considered MS as a possible outcome of ADS in children. This increased to 74% in year 1, 81% in year 2, and 87% in year 3.
The incidence of pediatric acquired demyelinating syndromes (ADS) is 0.9 per 100,000 Canadian children. ADS presentations are influenced by age.</description><identifier>ISSN: 0028-3878</identifier><identifier>EISSN: 1526-632X</identifier><identifier>DOI: 10.1212/01.wnl.0000339482.84392.bd</identifier><identifier>PMID: 19153370</identifier><identifier>CODEN: NEURAI</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Adolescent ; Age Distribution ; Biological and medical sciences ; Canada - epidemiology ; Central Nervous System Diseases - diagnosis ; Central Nervous System Diseases - drug therapy ; Central Nervous System Diseases - epidemiology ; Child ; Child, Preschool ; Demography ; Demyelinating Diseases - diagnosis ; Demyelinating Diseases - drug therapy ; Demyelinating Diseases - epidemiology ; Encephalomyelitis, Acute Disseminated - epidemiology ; Female ; Glucocorticoids - administration & dosage ; Humans ; Immunoglobulins, Intravenous - therapeutic use ; Incidence ; Infant ; Injections, Intravenous ; Magnetic Resonance Imaging ; Male ; Medical sciences ; Methylprednisolone - administration & dosage ; Myelitis, Transverse - epidemiology ; Nervous system (semeiology, syndromes) ; Nervous system as a whole ; Neurology ; Optic Neuritis - epidemiology ; Sex Distribution</subject><ispartof>Neurology, 2009-01, Vol.72 (3), p.232-239</ispartof><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c290t-5e32be5edc8922831768dbaf0dd6d806e203263bdfd10b9673a7dea27283d8253</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21059260$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19153370$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BANWELL, B</creatorcontrib><creatorcontrib>KENNEDY, J</creatorcontrib><creatorcontrib>SEBIRE, G</creatorcontrib><creatorcontrib>MEANEY, B</creatorcontrib><creatorcontrib>DILENGE, M.-E</creatorcontrib><creatorcontrib>LORTIE, A</creatorcontrib><creatorcontrib>WHITING, S</creatorcontrib><creatorcontrib>DOJA, A</creatorcontrib><creatorcontrib>LEVIN, S</creatorcontrib><creatorcontrib>MACDONALD, E. A</creatorcontrib><creatorcontrib>MEEK, D</creatorcontrib><creatorcontrib>WOOD, E</creatorcontrib><creatorcontrib>SADOVNICK, D</creatorcontrib><creatorcontrib>LOWRY, N</creatorcontrib><creatorcontrib>BUCKLEY, D</creatorcontrib><creatorcontrib>YIM, C</creatorcontrib><creatorcontrib>AWUKU, M</creatorcontrib><creatorcontrib>GUIMOND, C</creatorcontrib><creatorcontrib>COOPER, P</creatorcontrib><creatorcontrib>GRAND'MAISON, F</creatorcontrib><creatorcontrib>BAIRD, J. B</creatorcontrib><creatorcontrib>BHAN, V</creatorcontrib><creatorcontrib>BAR-OR, A</creatorcontrib><creatorcontrib>ARNOLD, D. L</creatorcontrib><creatorcontrib>MAGALHAES, S</creatorcontrib><creatorcontrib>WAMBERA, K</creatorcontrib><creatorcontrib>CONNOLLY, M. B</creatorcontrib><creatorcontrib>YAGER, J</creatorcontrib><creatorcontrib>MAH, J. K</creatorcontrib><creatorcontrib>SHAH, N</creatorcontrib><title>Incidence of acquired demyelination of the CNS in Canadian children</title><title>Neurology</title><addtitle>Neurology</addtitle><description>The incidence of acquired demyelination of the CNS (acquired demyelinating syndromes [ADS]) in children is unknown. It is important that physicians recognize the features of ADS to facilitate care and to appreciate the future risk of multiple sclerosis (MS).
To determine the incidence, clinical features, familial autoimmune history, and acute management of Canadian children with ADS.
Incidence and case-specific data were obtained through the Canadian Pediatric Surveillance Program from April 1, 2004, to March 31, 2007. Before study initiation, a survey was sent to all pediatric health care providers to determine awareness of MS as a potential outcome of ADS in children.
Two hundred nineteen children with ADS (mean age 10.5 years, range 0.66-18.0 years; female to male ratio 1.09:1) were reported. The most common presentations were optic neuritis (ON; n = 51, 23%), acute disseminated encephalomyelitis (ADEM; n = 49, 22%), and transverse myelitis (TM; n = 48, 22%). Children with ADEM were more likely to be younger than 10 years, whereas children with monolesional ADS (ON, TM, other) were more likely to be older than 10 years (p < 0.001). There were 73 incident cases per year, leading to an annual incidence of 0.9 per 100,000 Canadian children. A family history of MS was reported in 8%. Before study initiation, 65% of physicians indicated that they considered MS as a possible outcome of ADS in children. This increased to 74% in year 1, 81% in year 2, and 87% in year 3.
The incidence of pediatric acquired demyelinating syndromes (ADS) is 0.9 per 100,000 Canadian children. ADS presentations are influenced by age.</description><subject>Adolescent</subject><subject>Age Distribution</subject><subject>Biological and medical sciences</subject><subject>Canada - epidemiology</subject><subject>Central Nervous System Diseases - diagnosis</subject><subject>Central Nervous System Diseases - drug therapy</subject><subject>Central Nervous System Diseases - epidemiology</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Demography</subject><subject>Demyelinating Diseases - diagnosis</subject><subject>Demyelinating Diseases - drug therapy</subject><subject>Demyelinating Diseases - epidemiology</subject><subject>Encephalomyelitis, Acute Disseminated - epidemiology</subject><subject>Female</subject><subject>Glucocorticoids - administration & dosage</subject><subject>Humans</subject><subject>Immunoglobulins, Intravenous - therapeutic use</subject><subject>Incidence</subject><subject>Infant</subject><subject>Injections, Intravenous</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methylprednisolone - administration & dosage</subject><subject>Myelitis, Transverse - epidemiology</subject><subject>Nervous system (semeiology, syndromes)</subject><subject>Nervous system as a whole</subject><subject>Neurology</subject><subject>Optic Neuritis - epidemiology</subject><subject>Sex Distribution</subject><issn>0028-3878</issn><issn>1526-632X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkMFKJDEQhoMo6-juK0gj6K3bSsVOJ96kcV1B9KDC3kI6VY2RnrR2ZhDf3p51WOtSh__7q-AT4lhCJVHiGcjqPQ0VzKOUPTdYmXNlsepoRyxkjbrUCv_uigUAmlKZxuyLg5xfAOawsT_EvrSyVqqBhWhvUojEKXAx9oUPb-s4MRXEyw8eYvKrOKZNsnrmor17KGIqWp88RZ-K8BwHmjj9FHu9HzL_2u5D8fT76rH9U97eX9-0l7dlQAursmaFHddMwVhEo2SjDXW-ByJNBjQjKNSqo54kdFY3yjfEHpuZJYO1OhSnX3dfp_FtzXnlljEHHgafeFxnp7VB28gNePEFhmnMeeLevU5x6acPJ8FtFDqQblbovhW6fwpdR3P5aPtl3S2ZvqtbZzNwsgV8Dn7oJz8rzP85lFBb1KA-AUb3enk</recordid><startdate>20090120</startdate><enddate>20090120</enddate><creator>BANWELL, B</creator><creator>KENNEDY, J</creator><creator>SEBIRE, G</creator><creator>MEANEY, B</creator><creator>DILENGE, M.-E</creator><creator>LORTIE, A</creator><creator>WHITING, S</creator><creator>DOJA, A</creator><creator>LEVIN, S</creator><creator>MACDONALD, E. A</creator><creator>MEEK, D</creator><creator>WOOD, E</creator><creator>SADOVNICK, D</creator><creator>LOWRY, N</creator><creator>BUCKLEY, D</creator><creator>YIM, C</creator><creator>AWUKU, M</creator><creator>GUIMOND, C</creator><creator>COOPER, P</creator><creator>GRAND'MAISON, F</creator><creator>BAIRD, J. B</creator><creator>BHAN, V</creator><creator>BAR-OR, A</creator><creator>ARNOLD, D. L</creator><creator>MAGALHAES, S</creator><creator>WAMBERA, K</creator><creator>CONNOLLY, M. B</creator><creator>YAGER, J</creator><creator>MAH, J. K</creator><creator>SHAH, N</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20090120</creationdate><title>Incidence of acquired demyelination of the CNS in Canadian children</title><author>BANWELL, B ; KENNEDY, J ; SEBIRE, G ; MEANEY, B ; DILENGE, M.-E ; LORTIE, A ; WHITING, S ; DOJA, A ; LEVIN, S ; MACDONALD, E. A ; MEEK, D ; WOOD, E ; SADOVNICK, D ; LOWRY, N ; BUCKLEY, D ; YIM, C ; AWUKU, M ; GUIMOND, C ; COOPER, P ; GRAND'MAISON, F ; BAIRD, J. B ; BHAN, V ; BAR-OR, A ; ARNOLD, D. L ; MAGALHAES, S ; WAMBERA, K ; CONNOLLY, M. B ; YAGER, J ; MAH, J. K ; SHAH, N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c290t-5e32be5edc8922831768dbaf0dd6d806e203263bdfd10b9673a7dea27283d8253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adolescent</topic><topic>Age Distribution</topic><topic>Biological and medical sciences</topic><topic>Canada - epidemiology</topic><topic>Central Nervous System Diseases - diagnosis</topic><topic>Central Nervous System Diseases - drug therapy</topic><topic>Central Nervous System Diseases - epidemiology</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Demography</topic><topic>Demyelinating Diseases - diagnosis</topic><topic>Demyelinating Diseases - drug therapy</topic><topic>Demyelinating Diseases - epidemiology</topic><topic>Encephalomyelitis, Acute Disseminated - epidemiology</topic><topic>Female</topic><topic>Glucocorticoids - administration & dosage</topic><topic>Humans</topic><topic>Immunoglobulins, Intravenous - therapeutic use</topic><topic>Incidence</topic><topic>Infant</topic><topic>Injections, Intravenous</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methylprednisolone - administration & dosage</topic><topic>Myelitis, Transverse - epidemiology</topic><topic>Nervous system (semeiology, syndromes)</topic><topic>Nervous system as a whole</topic><topic>Neurology</topic><topic>Optic Neuritis - epidemiology</topic><topic>Sex Distribution</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BANWELL, B</creatorcontrib><creatorcontrib>KENNEDY, J</creatorcontrib><creatorcontrib>SEBIRE, G</creatorcontrib><creatorcontrib>MEANEY, B</creatorcontrib><creatorcontrib>DILENGE, M.-E</creatorcontrib><creatorcontrib>LORTIE, A</creatorcontrib><creatorcontrib>WHITING, S</creatorcontrib><creatorcontrib>DOJA, A</creatorcontrib><creatorcontrib>LEVIN, S</creatorcontrib><creatorcontrib>MACDONALD, E. A</creatorcontrib><creatorcontrib>MEEK, D</creatorcontrib><creatorcontrib>WOOD, E</creatorcontrib><creatorcontrib>SADOVNICK, D</creatorcontrib><creatorcontrib>LOWRY, N</creatorcontrib><creatorcontrib>BUCKLEY, D</creatorcontrib><creatorcontrib>YIM, C</creatorcontrib><creatorcontrib>AWUKU, M</creatorcontrib><creatorcontrib>GUIMOND, C</creatorcontrib><creatorcontrib>COOPER, P</creatorcontrib><creatorcontrib>GRAND'MAISON, F</creatorcontrib><creatorcontrib>BAIRD, J. B</creatorcontrib><creatorcontrib>BHAN, V</creatorcontrib><creatorcontrib>BAR-OR, A</creatorcontrib><creatorcontrib>ARNOLD, D. L</creatorcontrib><creatorcontrib>MAGALHAES, S</creatorcontrib><creatorcontrib>WAMBERA, K</creatorcontrib><creatorcontrib>CONNOLLY, M. B</creatorcontrib><creatorcontrib>YAGER, J</creatorcontrib><creatorcontrib>MAH, J. K</creatorcontrib><creatorcontrib>SHAH, N</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BANWELL, B</au><au>KENNEDY, J</au><au>SEBIRE, G</au><au>MEANEY, B</au><au>DILENGE, M.-E</au><au>LORTIE, A</au><au>WHITING, S</au><au>DOJA, A</au><au>LEVIN, S</au><au>MACDONALD, E. A</au><au>MEEK, D</au><au>WOOD, E</au><au>SADOVNICK, D</au><au>LOWRY, N</au><au>BUCKLEY, D</au><au>YIM, C</au><au>AWUKU, M</au><au>GUIMOND, C</au><au>COOPER, P</au><au>GRAND'MAISON, F</au><au>BAIRD, J. B</au><au>BHAN, V</au><au>BAR-OR, A</au><au>ARNOLD, D. L</au><au>MAGALHAES, S</au><au>WAMBERA, K</au><au>CONNOLLY, M. B</au><au>YAGER, J</au><au>MAH, J. K</au><au>SHAH, N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Incidence of acquired demyelination of the CNS in Canadian children</atitle><jtitle>Neurology</jtitle><addtitle>Neurology</addtitle><date>2009-01-20</date><risdate>2009</risdate><volume>72</volume><issue>3</issue><spage>232</spage><epage>239</epage><pages>232-239</pages><issn>0028-3878</issn><eissn>1526-632X</eissn><coden>NEURAI</coden><abstract>The incidence of acquired demyelination of the CNS (acquired demyelinating syndromes [ADS]) in children is unknown. It is important that physicians recognize the features of ADS to facilitate care and to appreciate the future risk of multiple sclerosis (MS).
To determine the incidence, clinical features, familial autoimmune history, and acute management of Canadian children with ADS.
Incidence and case-specific data were obtained through the Canadian Pediatric Surveillance Program from April 1, 2004, to March 31, 2007. Before study initiation, a survey was sent to all pediatric health care providers to determine awareness of MS as a potential outcome of ADS in children.
Two hundred nineteen children with ADS (mean age 10.5 years, range 0.66-18.0 years; female to male ratio 1.09:1) were reported. The most common presentations were optic neuritis (ON; n = 51, 23%), acute disseminated encephalomyelitis (ADEM; n = 49, 22%), and transverse myelitis (TM; n = 48, 22%). Children with ADEM were more likely to be younger than 10 years, whereas children with monolesional ADS (ON, TM, other) were more likely to be older than 10 years (p < 0.001). There were 73 incident cases per year, leading to an annual incidence of 0.9 per 100,000 Canadian children. A family history of MS was reported in 8%. Before study initiation, 65% of physicians indicated that they considered MS as a possible outcome of ADS in children. This increased to 74% in year 1, 81% in year 2, and 87% in year 3.
The incidence of pediatric acquired demyelinating syndromes (ADS) is 0.9 per 100,000 Canadian children. ADS presentations are influenced by age.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>19153370</pmid><doi>10.1212/01.wnl.0000339482.84392.bd</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-3878 |
| ispartof | Neurology, 2009-01, Vol.72 (3), p.232-239 |
| issn | 0028-3878 1526-632X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66829715 |
| source | MEDLINE; Alma/SFX Local Collection; Journals@Ovid Complete |
| subjects | Adolescent Age Distribution Biological and medical sciences Canada - epidemiology Central Nervous System Diseases - diagnosis Central Nervous System Diseases - drug therapy Central Nervous System Diseases - epidemiology Child Child, Preschool Demography Demyelinating Diseases - diagnosis Demyelinating Diseases - drug therapy Demyelinating Diseases - epidemiology Encephalomyelitis, Acute Disseminated - epidemiology Female Glucocorticoids - administration & dosage Humans Immunoglobulins, Intravenous - therapeutic use Incidence Infant Injections, Intravenous Magnetic Resonance Imaging Male Medical sciences Methylprednisolone - administration & dosage Myelitis, Transverse - epidemiology Nervous system (semeiology, syndromes) Nervous system as a whole Neurology Optic Neuritis - epidemiology Sex Distribution |
| title | Incidence of acquired demyelination of the CNS in Canadian children |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T13%3A56%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Incidence%20of%20acquired%20demyelination%20of%20the%20CNS%20in%20Canadian%20children&rft.jtitle=Neurology&rft.au=BANWELL,%20B&rft.date=2009-01-20&rft.volume=72&rft.issue=3&rft.spage=232&rft.epage=239&rft.pages=232-239&rft.issn=0028-3878&rft.eissn=1526-632X&rft.coden=NEURAI&rft_id=info:doi/10.1212/01.wnl.0000339482.84392.bd&rft_dat=%3Cproquest_cross%3E66829715%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66829715&rft_id=info:pmid/19153370&rfr_iscdi=true |